The study of plasma levels of sCD40 and sCD40L in Alzheimer’s disease and mild cognitive impairment
10.3969/j.issn.1002-0152.2016.08.003
- VernacularTitle:阿尔茨海默病与轻度认知障碍患者血浆sCD40及sCD40L浓度研究
- Author:
Ling LI
;
Xiaomei ZHONG
;
Haishan SHI
;
Le HOU
;
Xinni LUO
;
Yanhua WANG
;
Guoyan HU
;
Xinru CHEN
;
Wenru ZHANG
;
Ben CHEN
;
Qi PENG
;
Yuping NING
- Publication Type:Journal Article
- Keywords:
Alzheimer’s Disease;
Amnestic mild cognitive impairment;
sCD40;
sCD40L
- From:
Chinese Journal of Nervous and Mental Diseases
2016;42(8):460-464
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the plasma levels of soluble CD40 (sCD40) and soluble CD40 ligand (sCD40L) in the patients with Alzheimer’s disease (AD) and those with amnestic mild cognitive impairment (aMCI). Methods The levels of plasma sCD40 and sCD40L were measured in 20 patients with AD, 35 patients with aMCI, and 32 cognitively normal controls (NC) using commercially available ELISAs. The cognitive function of AD and aMCI patients was mea?sured by mini-mental state examination (MMSE). Results There were significant differences in plasma sCD40 among AD, aMCI and NC groups (P<0.05) as the medians (the upper and lower quartiles) of plasma levels were 123.3 (97.4, 149.5) pg/mL, 102.9 (63.6, 124.0) pg/mL and 70.66 (51.0, 90.8) pg/mL, respectively. There were significant differences in plasma sCD40L among AD, aMCI and NC groups (P<0.05) as plasma levels were 537.0 (316.0, 1134.0) pg/mL, 316.0 (190.0,546.0) pg/mL and 167.0 (107.5,478.0) pg/mL. A negative correlation between the plasma concentrations of sCD40L and the MMSE scores was found in aMCI patients (r=-0.736, P<0.001). Conclusions There are relevant chang?es of plasma sCD40 and sCD40L levels in patients with AD and aMCI. The present results suggest that plasma levels of sCD40 and sCD40L may be appropriate biomarkers for AD patients and indicate that CD40-CD40L signaling may be in?volved in AD pathophysiology.
